GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Eleven analysts give GH Research an average recommendation of Moderate Buy (9 buys, 1 hold, 1 sell) with an average 12‑month price target of $40.13, well above the current share price.
• Large institutions have been increasing exposure — Lynx1 Capital raised its stake 27.5% to 8.60M shares, RTW and Millennium also added positions, and institutional investors now own 56.9% of the company.
• GH Research is a clinical‑stage biotech developing psychedelic‑inspired treatments (lead program GH001, inhaled 5‑MeO‑DMT for treatment‑resistant depression); the stock trades around $21.28 with a $1.32B market cap and reported EPS of -$0.23 last quarter, beating estimates.

GH Research PLC (NASDAQ:GHRS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $40.1250.

Several research firms have commented on GHRS. Needham & Company LLC lifted their target price on shares of GH Research from $31.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, March 6th. Royal Bank Of Canada raised their price objective on GH Research from $33.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, January 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of GH Research in a research report on Tuesday, April 21st. Guggenheim set a $34.00 target price on GH Research and gave the company a "buy" rating in a research note on Tuesday, March 10th. Finally, Wolfe Research set a $39.00 target price on GH Research in a research report on Tuesday, January 6th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Lynx1 Capital Management LP boosted its position in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company's stock worth $122,997,000 after acquiring an additional 1,854,238 shares during the last quarter. RTW Investments LP increased its position in GH Research by 6.5% during the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company's stock worth $75,359,000 after purchasing an additional 364,251 shares during the last quarter. Avoro Capital Advisors LLC purchased a new position in GH Research during the fourth quarter worth approximately $22,860,000. Millennium Management LLC raised its stake in GH Research by 324.1% during the third quarter. Millennium Management LLC now owns 863,602 shares of the company's stock worth $12,350,000 after purchasing an additional 659,957 shares during the period. Finally, Jefferies Financial Group Inc. boosted its holdings in shares of GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company's stock valued at $9,046,000 after purchasing an additional 2,988 shares during the last quarter. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Trading Down 1.9%

NASDAQ:GHRS opened at $21.28 on Wednesday. GH Research has a 12-month low of $9.46 and a 12-month high of $24.66. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -26.60 and a beta of 1.27. The company's 50-day moving average is $16.16 and its two-hundred day moving average is $15.08.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.06. On average, equities research analysts forecast that GH Research will post -1.52 earnings per share for the current fiscal year.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm's lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.